The lawsuit centers on claims that Unicycive failed to audit a third-party manufacturing vendor, leaving the company without a legitimate basis to confirm that FDA-cited deficiencies had been resolved. According to the complaint, these omissions created an undisclosed risk that regulatory approval for oxylanthanum carbonate would face significant delays. When these operational realities surfaced, the market value of the company’s securities fell, resulting in financial losses for shareholders.

Investors wishing to participate in the litigation must file a motion with the court by the November deadline. While the Rosen Law Firm is currently organizing the case, no class has been formally certified. Shareholders retain the right to select their own counsel, remain absent members, or pursue independent legal action. Those interested in joining the current case can contact Phillip Kim at the Rosen Law Firm for further guidance on the contingency-based representation process.